None

Amarin's Sloooow Vascepa Launch

BEDMINSTER, NJ (TheStreet) -- The early verdict on Amarin's Vascepa launch: Slow. Early verdicts are not final verdicts, so no one is saying Amarin is doomed just two months into the launch of its...

Feuerstein: Amarin's Sloooow Vascepa Launch

BEDMINSTER, NJ (TheStreet) -- The early verdict on Amarin's Vascepa launch: Slow. Early verdicts are not final verdicts, so no one is saying Amarin is doomed just two months into the launch of its...

Amarin Has Upside Potential With Drug

By Osman Gulseven:By: Ishtiaq AhmedAmarin Corporation (AMRN) stock has become sluggish in recent weeks due to a delay in the decision about NCE status of Vascepa. The company has been able to amass an...

Amarin: Watch For Big Moves

By Osman Gulseven: Edited By Adam Isaac Amarin Corporation (AMRN) develops and commercializes therapeutics to improve cardiovascular health. Amarin got approval for its drug Vascepa on July 27, 2012...

Buy Amarin: Acquisition Prospects Just Got Better

ByStock Whisper:Amarin (AMRN) developed a star product in Vascepa, which received FDA approval in July 2011. The FDA nod for its fish oil Vascepa was a smooth process for Amarin, but the NCE (new chem...

Amarin: The Bull Argument (Or How I Learned To Stop Worrying And Love Vascepa)

ByBond Wells:The bull argument for Amarin's (AMRN) Vascepa is simple: it works better than Lovaza, it doesn't have the negative aspects, it doesn't have an atrial fibrillation warning, it is applying...

Vascepa Launch Puts Amarin's Valuation To The Test

By Brian L. Wilson:It seems as if the market is taking a relatively neutral stance on Amarin (AMRN) while we wait for more details about the ongoing market launch of Vascepa. We're also seeing less sp...

Amarin's Descent To $5

By Medhanie:In my previous article, I stated that without a five year New Chemical Exclusivity (NCE), Amarin (AMRN) is a $6 stock and maybe as low as $5. It seems that the market is starting to come a...

None